To augment or not to augment? That is the question. ©IrenaBraga/ShutterstockRelated content:Do Things Come in (Omega)-3s?
What’s New in Our Understanding of Schizophrenia
During the past 5 years, new insights into the pathophysiological processes that underlie schizophrenia have been revealed. Here's a quick update.
Marijuana and the Psychiatric Patient
Marijuana-related problems fall well within the scope of psychiatric practice: many patients use marijuana, which is likely to affect their psychiatric symptoms and response to treatment.
Therapy for Cognition: Restoring the Self in Bipolar Disorder
Functional remediation therapy addresses the cognitive problems of the nearly 50% of patients who remain impaired even when euthymic.
Ultrahigh-Risk Psychosis: Do Things Come in (Omega)-3s?
Can dietary supplementation decrease the risk of transition to psychosis?
Antipsychotic Augmentation vs Monotherapy in Schizophrenia
To augment or not to augment? That is the question.
Deborah Danner and the Suffering of Schizophrenia
The nightmarish reality of psychosis is vividly detailed by Deborah Danner, a woman with self-described schizophrenia, recently shot to death by a New York City policeman.
Antipsychotics and Breast Cancer Risk
Are antipsychotics associated with an increased risk of breast cancer?
Marijuana—Legal, But Not by Prescription
What are the pros and cons of marijuana use? Dr Andrew Saxon gives his viewpoint on why he is against medical marijuana but in favor of legalization of recreational use of marijuana.
New Psychopharmacology Algorithms
Dr David Osser offers compelling reasons why you might want to take a look at these 7 algorithms, each of which offers actionable consultations—usually in under 2 minutes.
New Research in the Genetics of Autism
An expert discusses the clinical, biological, and genetic components of de novo mutations and autism spectrum disorders.
Evidence-Based Practices in Managing Agitation and Aggression
A video summarizing key points of a presentation titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”
Advances in Schizophrenia in 2016
The year 2016 marks a critical time in our understanding of and approaches to treating schizophrenia spectrum disorders.
Earn CME Credits for reading Psychiatric Times articles. Click here to go to our free online CME activities.
By clicking Accept, you agree to become a member of the UBM Medica Community.